Does asthma affect morbidity or severity of COVID-19?

Affiliations

¹ Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan. Electronic address: matsumoto-k@ncchd.go.jp.
² Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.

Editorial

Kenji Matsumoto et al. J Allergy Clin Immunol. 2020 Jul.

. 2020 Jul;146(1):55-57.

doi: 10.1016/j.jaci.2020.05.017. Epub 2020 May 26.

¹ Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan. Electronic address: matsumoto-k@ncchd.go.jp.
² Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan.

No abstract available

Keywords: Coronavirus disease 2019; IFN; T2 cytokines; angiotensin-converting enzyme 2; asthma.

References

1. Zheng X.Y., Xu Y.J., Guan W.J., Lin L.F. Regional, age and respiratory-secretion-specific prevalence of respiratory viruses associated with asthma exacerbation: a literature review. Arch Virol. 2018;163:845–853. - PMC - PubMed
1. Edwards M.R., Strong K., Cameron A., Walton R.P., Jackson D.J., Johnston S.L. Viral infections in allergy and immunology: how allergic inflammation influences viral infections and illness. J Allergy Clin Immunol. 2017;140:909–920. - PMC - PubMed
1. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan [published online ahead of print April 12, 2020]. J Allergy Clin Immunol 10.1016/j.jaci.2020.04.006. - DOI - PMC - PubMed
1. Singer AJ, Morley EJ, Meyers K, Fernandes R, Rowe AL, Viccellio P, et al. Cohort of 4404 persons under investigation for COVID-19 in a NY hospital and predictors of ICU care and ventilation [published online ahead of print April 23, 2020]. Ann Emerg Med 10.2139/ssrn.3583678. - DOI - PMC - PubMed
1. Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. - PMC - PubMed